Slimaluma® receives FDA GRAS statusOctober 2, 2014
Slimaluma, a patented extract of Caralluma fimbriata offered by Gencor, has received notification from the Food and Drug Administration (FDA) of no objection to it being considered GRAS (Generally Recognized As Safe) for use in meal replacement products.
Gencor is offering Slimaluma for use as an ingredient in meal replacement products such as baked goods, bars, soups, drinks and shakes, at levels up to 350 milligrams per serving (700 milligrams per day). Slimaluma is currently in the market as an ingredient in dietary supplements and is effective in reducing waist circumference and suppressing appetite, when combined with healthy diet and exercise.
For more information about Slimaluma, please visit www.gencorpacific.com
Ingredient Profile: ActivAMP™
Extracted from the adaptogenic herb Gynostemma pentaphyllum, ActivAMP activates the energy-switching enzyme AMPK, and thus promotes many of the metabolic and health benefits of exercise.
ActivAMP’s product benefits include:
Email us for more information at email@example.com.
Validated, Natural Weight Management Tools
By Dr. Paul Clayton
As people everywhere get heavier, so too does the burden of weight-related health problems. Pharmaceuticals can be addictive, too toxic for long-term use and/or ineffective. Some natural products, however, are emerging as validated tools for healthy weight management.
The food plant Caralluma fimbriata, which is still used as a natural appetite suppressant in parts of India, contains compounds that are safe and effective appetite suppressants. These compounds have been intensively researched by Gencor, which has developed a standardized and patented extract of C. fimbriata containing tightly controlled levels of pregnane glycosides and branded as Slimaluma.
Safety is critical in products designed for long-term use. Unsurprisingly, as it is derived from a food plant, Slimaluma has no reports of adverse effects; an acute oral toxicity study on rats showed no toxicity at doses up to 5g/kg, i.e. 5000 times the clinically effective dose. Slimaluma recently received notification from the Food and Drug Administration (FDA) of no objection to it being considered GRAS (Generally Recognized as Safe) for use in meal replacement products.
> Read More
Gencor in the News:
Study supports CFE for management of insulin resistance
A study of Wistar rats recently published in the Journal of Physiology and Biochemistry concludes that Caralluma fimbriata extract (CFE) may be beneficial for the suppression of high-fat diet-induced insulin resistance and oxidative stress. The study used Gencor’s patented extract of Caralluma Fimbriata, the appetite suppressant known as Slimaluma.
The study found that feeding CFE to rats prevented the development of health-threatening disorders such as hyperglycemia, hyperinsulinemia, hyperleptinemia and hypertriglyceridemia, as well as reducing oxidative stress.
“The results of this study are a welcome addition to the growing body of clinical research related to healthy weight management,” said Dr. Paul Clayton, chief scientific advisor at Gencor. “It also provides additional support forCaralluma fimbriata’s long history of safe and efficacious use.”
Join Us at SupplySide West!
Gencor looks forward to seeing you
at SupplySide West, Oct. 8-9, 2014,
at booth #34087.
Meet our team and see first-hand how Gencor is your source for unique botanical ingredients that meet your customer’s changing health needs.